Initiating and potentiating role of platelets in tissue factor‐induced thrombin generation in the presence of plasma: subject‐dependent variation in thrombogram characteristics
The hemostatic activity of plasma is determined by platelet activation and coagulation, which processes are mutually stimulatory. We studied this interaction by measuring the cleavage of fluorescent thrombin substrate in platelet‐rich plasma (PRP), using the calibrated thrombogram method. In freshly...
Saved in:
| Published in | Journal of thrombosis and haemostasis Vol. 2; no. 3; pp. 476 - 484 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Science Inc
01.03.2004
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The hemostatic activity of plasma is determined by platelet activation and coagulation, which processes are mutually stimulatory. We studied this interaction by measuring the cleavage of fluorescent thrombin substrate in platelet‐rich plasma (PRP), using the calibrated thrombogram method. In freshly isolated human plasma, thrombin formation triggered by tissue factor was fully dependent on the presence of platelets. It was abolished by annexin A5, indicating dependence on phosphatidylserine (PS) exposure at activated platelets. Comparison of plasmas from various subjects showed considerable interindividual variation in total amount of thrombin generation, regardless of whether platelets or PS‐containing phospholipids were present. Integrin αIIbβ3 antagonists and ADP receptor blockage, but not aspirin, decreased the rate of thrombin generation (thrombin peak level) and extended the time of onset. Platelet inhibition with cAMP‐elevating agents decreased the thrombin‐forming rate, but surprisingly shortened the onset time. Stimulation of platelets with agonists of Gi/q‐coupled receptors and, to a larger extent, with collagen or Ca2+‐ionophore increased the rate of thrombin generation and shortened its onset. In PRP from donors with low and high generation, platelet inhibitors and activators were similarly effective. Taken together, these results indicate that, in tissue factor‐triggered PRP, PS exposure on activated platelets regulates both onset and rate of thrombin generation. However, coagulant activity rather than platelet activation determines the total amount of thrombin formed, i.e. the endogenous thrombin potential. Thus, kinetics of thrombin generation in PRP are controlled by platelet inhibitors and agonists, but the process is restricted in amount by the subject‐dependent variation in coagulation. |
|---|---|
| AbstractList | The hemostatic activity of plasma is determined by platelet activation and coagulation, which processes are mutually stimulatory. We studied this interaction by measuring the cleavage of fluorescent thrombin substrate in platelet‐rich plasma (PRP), using the calibrated thrombogram method. In freshly isolated human plasma, thrombin formation triggered by tissue factor was fully dependent on the presence of platelets. It was abolished by annexin A5, indicating dependence on phosphatidylserine (PS) exposure at activated platelets. Comparison of plasmas from various subjects showed considerable interindividual variation in total amount of thrombin generation, regardless of whether platelets or PS‐containing phospholipids were present. Integrin αIIbβ3 antagonists and ADP receptor blockage, but not aspirin, decreased the rate of thrombin generation (thrombin peak level) and extended the time of onset. Platelet inhibition with cAMP‐elevating agents decreased the thrombin‐forming rate, but surprisingly shortened the onset time. Stimulation of platelets with agonists of Gi/q‐coupled receptors and, to a larger extent, with collagen or Ca2+‐ionophore increased the rate of thrombin generation and shortened its onset. In PRP from donors with low and high generation, platelet inhibitors and activators were similarly effective. Taken together, these results indicate that, in tissue factor‐triggered PRP, PS exposure on activated platelets regulates both onset and rate of thrombin generation. However, coagulant activity rather than platelet activation determines the total amount of thrombin formed, i.e. the endogenous thrombin potential. Thus, kinetics of thrombin generation in PRP are controlled by platelet inhibitors and agonists, but the process is restricted in amount by the subject‐dependent variation in coagulation. The hemostatic activity of plasma is determined by platelet activation and coagulation, which processes are mutually stimulatory. We studied this interaction by measuring the cleavage of fluorescent thrombin substrate in platelet-rich plasma (PRP), using the calibrated thrombogram method. In freshly isolated human plasma, thrombin formation triggered by tissue factor was fully dependent on the presence of platelets. It was abolished by annexin A5, indicating dependence on phosphatidylserine (PS) exposure at activated platelets. Comparison of plasmas from various subjects showed considerable interindividual variation in total amount of thrombin generation, regardless of whether platelets or PS-containing phospholipids were present. Integrin alphaIIbbeta3 antagonists and ADP receptor blockage, but not aspirin, decreased the rate of thrombin generation (thrombin peak level) and extended the time of onset. Platelet inhibition with cAMP-elevating agents decreased the thrombin-forming rate, but surprisingly shortened the onset time. Stimulation of platelets with agonists of Gi/q-coupled receptors and, to a larger extent, with collagen or Ca2+-ionophore increased the rate of thrombin generation and shortened its onset. In PRP from donors with low and high generation, platelet inhibitors and activators were similarly effective. Taken together, these results indicate that, in tissue factor-triggered PRP, PS exposure on activated platelets regulates both onset and rate of thrombin generation. However, coagulant activity rather than platelet activation determines the total amount of thrombin formed, i.e. the endogenous thrombin potential. Thus, kinetics of thrombin generation in PRP are controlled by platelet inhibitors and agonists, but the process is restricted in amount by the subject-dependent variation in coagulation.The hemostatic activity of plasma is determined by platelet activation and coagulation, which processes are mutually stimulatory. We studied this interaction by measuring the cleavage of fluorescent thrombin substrate in platelet-rich plasma (PRP), using the calibrated thrombogram method. In freshly isolated human plasma, thrombin formation triggered by tissue factor was fully dependent on the presence of platelets. It was abolished by annexin A5, indicating dependence on phosphatidylserine (PS) exposure at activated platelets. Comparison of plasmas from various subjects showed considerable interindividual variation in total amount of thrombin generation, regardless of whether platelets or PS-containing phospholipids were present. Integrin alphaIIbbeta3 antagonists and ADP receptor blockage, but not aspirin, decreased the rate of thrombin generation (thrombin peak level) and extended the time of onset. Platelet inhibition with cAMP-elevating agents decreased the thrombin-forming rate, but surprisingly shortened the onset time. Stimulation of platelets with agonists of Gi/q-coupled receptors and, to a larger extent, with collagen or Ca2+-ionophore increased the rate of thrombin generation and shortened its onset. In PRP from donors with low and high generation, platelet inhibitors and activators were similarly effective. Taken together, these results indicate that, in tissue factor-triggered PRP, PS exposure on activated platelets regulates both onset and rate of thrombin generation. However, coagulant activity rather than platelet activation determines the total amount of thrombin formed, i.e. the endogenous thrombin potential. Thus, kinetics of thrombin generation in PRP are controlled by platelet inhibitors and agonists, but the process is restricted in amount by the subject-dependent variation in coagulation. The hemostatic activity of plasma is determined by platelet activation and coagulation, which processes are mutually stimulatory. We studied this interaction by measuring the cleavage of fluorescent thrombin substrate in platelet-rich plasma (PRP), using the calibrated thrombogram method. In freshly isolated human plasma, thrombin formation triggered by tissue factor was fully dependent on the presence of platelets. It was abolished by annexin A5, indicating dependence on phosphatidylserine (PS) exposure at activated platelets. Comparison of plasmas from various subjects showed considerable interindividual variation in total amount of thrombin generation, regardless of whether platelets or PS-containing phospholipids were present. Integrin alphaIIbbeta3 antagonists and ADP receptor blockage, but not aspirin, decreased the rate of thrombin generation (thrombin peak level) and extended the time of onset. Platelet inhibition with cAMP-elevating agents decreased the thrombin-forming rate, but surprisingly shortened the onset time. Stimulation of platelets with agonists of Gi/q-coupled receptors and, to a larger extent, with collagen or Ca2+-ionophore increased the rate of thrombin generation and shortened its onset. In PRP from donors with low and high generation, platelet inhibitors and activators were similarly effective. Taken together, these results indicate that, in tissue factor-triggered PRP, PS exposure on activated platelets regulates both onset and rate of thrombin generation. However, coagulant activity rather than platelet activation determines the total amount of thrombin formed, i.e. the endogenous thrombin potential. Thus, kinetics of thrombin generation in PRP are controlled by platelet inhibitors and agonists, but the process is restricted in amount by the subject-dependent variation in coagulation. |
| Author | Vanschoonbeek, K. Van Kampen, R. J. W. Giesen, P. L. A. Feijge, M. A. H. Hemker, H. C. Heemskerk, J. W. M. Kenis, H. |
| Author_xml | – sequence: 1 givenname: K. surname: Vanschoonbeek fullname: Vanschoonbeek, K. – sequence: 2 givenname: M. A. H. surname: Feijge fullname: Feijge, M. A. H. – sequence: 3 givenname: R. J. W. surname: Van Kampen fullname: Van Kampen, R. J. W. – sequence: 4 givenname: H. surname: Kenis fullname: Kenis, H. – sequence: 5 givenname: H. C. surname: Hemker fullname: Hemker, H. C. – sequence: 6 givenname: P. L. A. surname: Giesen fullname: Giesen, P. L. A. – sequence: 7 givenname: J. W. M. surname: Heemskerk fullname: Heemskerk, J. W. M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15009466$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc9uFSEYxYmpsX_0FQwrd3eEYf4wxpiYRm2bJm7qmjDwcS83MzACU9udj-DD-EQ-icy9vY1xo2z4Auf8TuCcoiPnHSCEKSloXq-3Ba0ZX7UdY0VJSFUQ0lBe3D1BJ_sLzpqjw5xFx-g0xi0htKtL8gwd05qQrmqaE_Tz0tlkZbJujaXTePIJ3OEg-AGwN3gaZIIBUsTW4WRjnAEbqZIPv77_sE7PCjROm-DHPgvW4CBkgHc7-QbwFCCCUwdWHOUbHOd-CyplgIYJnM6p-FYG-4dx4fl1kCNWGxlyHgQbk1XxOXpq5BDhxcN-hr58_HBzfrG6_vzp8vz99UpVnPAV14SYkmtW96YzhJZVw3VfGlrSpqtUo5UyjKqWcmbaChTpNYBp-6auWt0yxs7Qqz13Cv7rDDGJ0UYFwyAd-DmKlraZxEgWvnwQzv0IWkzBjjLci8M_Z8G7vUAFH2MAI5RNu6emIO0gKBFLsWIrls7E0plYihW7YsVdBvC_AI8Z_7a-3Vu_2QHu_9snrm4u8sB-A8r5wc4 |
| CitedBy_id | crossref_primary_10_1080_10739680701653517 crossref_primary_10_1371_journal_pone_0055688 crossref_primary_10_3390_ijms22189701 crossref_primary_10_1093_jn_137_1_7 crossref_primary_10_1111_j_1537_2995_2008_01872_x crossref_primary_10_1002_ajh_20262 crossref_primary_10_1053_j_seminoncol_2014_04_009 crossref_primary_10_1111_j_1365_2516_2011_02601_x crossref_primary_10_1182_blood_2011_03_343061 crossref_primary_10_1093_eurheartj_ehn195 crossref_primary_10_1160_TH05_10_0701 crossref_primary_10_1016_j_jtcvs_2005_08_058 crossref_primary_10_1016_j_jtha_2024_05_033 crossref_primary_10_1111_jth_12045 crossref_primary_10_1111_j_1365_2141_2008_07267_x crossref_primary_10_1182_blood_2008_07_171066 crossref_primary_10_1038_s41569_023_00854_6 crossref_primary_10_1055_a_1450_8300 crossref_primary_10_5482_HAMO_14_09_0047 crossref_primary_10_3389_fcvm_2020_608391 crossref_primary_10_1080_00365513_2018_1427280 crossref_primary_10_1111_j_1365_2141_2005_05820_x crossref_primary_10_1111_jth_14751 crossref_primary_10_1111_j_1365_2141_2005_05612_x crossref_primary_10_1111_j_1423_0410_2010_01337_x crossref_primary_10_1111_j_1538_7836_2005_01630_x crossref_primary_10_1016_j_redox_2025_103489 crossref_primary_10_1080_09537100600757448 crossref_primary_10_3390_ijms21093294 crossref_primary_10_1016_S0049_3848_14_50024_2 crossref_primary_10_3390_jcm10051114 crossref_primary_10_1016_j_jcyt_2013_01_219 crossref_primary_10_1016_j_thromres_2013_07_005 crossref_primary_10_1016_j_thromres_2017_03_023 crossref_primary_10_1016_j_actbio_2019_01_032 crossref_primary_10_1134_S1062359006050104 crossref_primary_10_1111_j_1742_4658_2007_06207_x crossref_primary_10_3389_fcvm_2022_919495 crossref_primary_10_1038_s41598_020_68379_3 crossref_primary_10_1111_j_1538_7836_2011_04427_x crossref_primary_10_1016_j_thromres_2016_01_006 crossref_primary_10_1016_j_transci_2020_102852 crossref_primary_10_1177_1076029611429122 crossref_primary_10_1111_ijlh_12634 crossref_primary_10_1016_j_niox_2018_03_008 crossref_primary_10_1213_ANE_0b013e3181e9ed15 crossref_primary_10_1111_j_1365_2516_2012_02867_x crossref_primary_10_1111_jth_13007 crossref_primary_10_1182_blood_2004_12_4856 crossref_primary_10_1111_j_1537_2995_2007_01575_x crossref_primary_10_1186_1742_4682_11_17 crossref_primary_10_1007_s00018_012_1033_2 crossref_primary_10_1161_01_ATV_0000137119_28893_0b crossref_primary_10_1111_j_1538_7836_2005_01127_x crossref_primary_10_1182_blood_2010_01_262683 crossref_primary_10_1309_AJCPC5C4AGFRDKMX crossref_primary_10_1016_j_thromres_2013_04_007 crossref_primary_10_1186_1477_9560_3_16 crossref_primary_10_3390_cancers10110441 crossref_primary_10_1016_S0049_3848_11_70007_X crossref_primary_10_1016_j_thromres_2013_04_004 crossref_primary_10_1016_j_tmrv_2009_09_004 crossref_primary_10_1007_s11239_020_02346_7 crossref_primary_10_1111_jth_14786 crossref_primary_10_1111_jth_15595 crossref_primary_10_1080_09537104_2020_1742310 crossref_primary_10_1080_09537104_2017_1294680 crossref_primary_10_1007_s11239_006_9046_z crossref_primary_10_1111_j_1423_0410_2011_01575_x crossref_primary_10_21661_r_117279 crossref_primary_10_1016_j_athoracsur_2005_05_085 crossref_primary_10_1111_j_1538_7836_2009_03514_x crossref_primary_10_1002_cmdc_201100560 crossref_primary_10_1016_j_blre_2013_12_001 crossref_primary_10_1016_j_thromres_2017_06_027 crossref_primary_10_3389_fcvm_2022_865166 crossref_primary_10_1016_j_jtha_2023_12_037 crossref_primary_10_1111_j_1538_7836_2012_04716_x crossref_primary_10_1016_j_febslet_2006_08_082 crossref_primary_10_2217_14796678_2_4_503 crossref_primary_10_1016_j_ijsu_2015_10_011 crossref_primary_10_1161_01_ATV_0000257204_82396_2b crossref_primary_10_1160_TH13_01_0075 crossref_primary_10_1007_s00390_005_0531_y crossref_primary_10_1016_j_atherosclerosis_2004_12_037 crossref_primary_10_1161_ATVBAHA_111_242818 crossref_primary_10_1111_j_1537_2995_2012_03610_x crossref_primary_10_1177_1074248415578172 crossref_primary_10_1111_j_1778_428X_2006_00018_x crossref_primary_10_1016_j_thromres_2007_08_023 crossref_primary_10_1182_bloodadvances_2023010027 crossref_primary_10_1126_scitranslmed_aah4923 crossref_primary_10_1016_j_tmrv_2007_05_004 crossref_primary_10_1053_j_jvca_2019_12_030 crossref_primary_10_5482_HAMO_13_10_0054 crossref_primary_10_1016_j_jtha_2024_02_007 crossref_primary_10_3389_fbioe_2020_584050 crossref_primary_10_1007_BF03010326 crossref_primary_10_1111_jth_14008 crossref_primary_10_1016_j_angio_2014_03_001 crossref_primary_10_1182_bloodadvances_2017013573 crossref_primary_10_1111_j_1365_2141_2006_06453_x crossref_primary_10_1160_TH13_06_0493 crossref_primary_10_1074_jbc_M611367200 crossref_primary_10_1111_jth_12233 crossref_primary_10_1016_j_thromres_2019_03_015 crossref_primary_10_1097_01_mbc_0000214708_73374_ce |
| Cites_doi | 10.1055/s-0037-1614169 10.1159/000071636 10.1016/j.tips.2003.09.002 10.1055/s-0037-1616534 10.1111/j.1432-1033.1997.00547.x 10.1046/j.1365-2141.1998.00844.x 10.1016/S0149-2918(02)85149-9 10.1055/s-0038-1642666 10.1055/s-0037-1614996 10.1055/s-0037-1613868 10.1172/JCI118859 10.1055/s-0037-1613336 10.1182/blood.V96.7.2469 10.1161/01.CIR.97.17.1680 10.1097/00001721-199809000-00008 10.1182/blood.V97.8.2314 10.1161/01.ATV.21.4.618 10.1046/j.1365-2141.2000.02208.x 10.1161/01.ATV.0000031340.68494.34 10.1182/blood.V95.5.1694.005k24_1694_1702 10.1055/s-0038-1646521 10.1074/jbc.M205902200 10.1182/blood.V90.7.2615 10.1055/s-0037-1614050 10.1161/01.ATV.19.12.2841 10.1055/s-0037-1613209 10.1055/s-0037-1613975 10.1046/j.1538-7836.2003.00077.x 10.1111/j.1432-1033.1982.tb05898.x 10.1182/blood.V89.4.1121 10.1016/S0006-2952(98)00348-7 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1111/j.1538-7933.2004.00618.x |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7836 |
| EndPage | 484 |
| ExternalDocumentID | 15009466 10_1111_j_1538_7933_2004_00618_x JTH618 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 05W 1OC 24P 29L 2WC 31~ 33P 36B 3SF 4.4 52U 52V 53G 5GY 5VS 66C 8-0 8-1 A00 AAESR AAEVG AAHHS AALRI AAONW AASGY AAXRX AAXUO AAZKR ABCUV ABDBF ABJNI ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADVLN ADXAS ADZMN AEEZP AEIMD AENEX AEQDE AFBPY AFEBI AFGKR AFJKZ AFPWT AFZJQ AHMBA AIACR AITUG AIURR AIWBW AJAOE AJBDE AKRWK ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMRAJ AMYDB ATUGU AZBYB AZVAB BAWUL BHBCM BMXJE BOGZA BRXPI C45 CAG COF CS3 DCZOG DIK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBS EJD EMB EMK ESX F5P FDB FIJ FUBAC G-S GODZA HZ~ IHE IPNFZ IX1 KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES M41 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OIG OK1 OVD P2P P2W P4E PQQKQ ROL SUPJJ SV3 TEORI TR2 W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WVDHM WYJ ZZTAW AAYWO AAYXX ACVFH ADCNI AEUPX AFPUW AGCQF AIGII AKBMS AKYEP APXCP CITATION CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY |
| ID | FETCH-LOGICAL-c4808-8d00f28d35bf9f012468db2f121694c6dccf31c7183f74ec0bdeef7b6547d7333 |
| IEDL.DBID | DR2 |
| ISSN | 1538-7933 1538-7836 |
| IngestDate | Fri Jul 11 16:36:21 EDT 2025 Thu Jan 02 21:58:17 EST 2025 Thu Apr 24 23:11:12 EDT 2025 Tue Jul 01 04:29:13 EDT 2025 Wed Jan 22 16:19:47 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4808-8d00f28d35bf9f012468db2f121694c6dccf31c7183f74ec0bdeef7b6547d7333 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://cris.maastrichtuniversity.nl/en/publications/0167f4f6-463b-4eb5-8155-16b1d5173e1e |
| PMID | 15009466 |
| PQID | 71716930 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_71716930 pubmed_primary_15009466 crossref_citationtrail_10_1111_j_1538_7933_2004_00618_x crossref_primary_10_1111_j_1538_7933_2004_00618_x wiley_primary_10_1111_j_1538_7933_2004_00618_x_JTH618 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | March 2004 2004-03-00 2004-Mar 20040301 |
| PublicationDateYYYYMMDD | 2004-03-01 |
| PublicationDate_xml | – month: 03 year: 2004 text: March 2004 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | Journal of thrombosis and haemostasis |
| PublicationTitleAlternate | J Thromb Haemost |
| PublicationYear | 2004 |
| Publisher | Blackwell Science Inc |
| Publisher_xml | – name: Blackwell Science Inc |
| References | 1995; 74 1989; 61 1997; 89 2002; 277 1982; 122 2000; 95 2000; 110 1996; 98 2001; 86 2003; 33 2001; 21 1997; 90 1997; 249 1999; 19 2002; 24 2000; 96 2002; 88 2002; 22 1999; 57 2000; 83 2003; 24 1964 2000; 84 2003; 1 1998; 102 1998; 97 2001; 97 1998; 9 1998; 79 Mascelli (10.1111/j.1538-7933.2004.00618.x_bb0130) 1998; 97 Monroe (10.1111/j.1538-7933.2004.00618.x_bb0025) 2002; 22 Hemker (10.1111/j.1538-7933.2004.00618.x_bb0100) 2003; 33 Siljander (10.1111/j.1538-7933.2004.00618.x_bb0110) 2001; 21 Hérault (10.1111/j.1538-7933.2004.00618.x_bb0050) 1998; 79 Heemskerk (10.1111/j.1538-7933.2004.00618.x_bb0135) 1997; 90 Heemskerk (10.1111/j.1538-7933.2004.00618.x_bb0020) 2002; 88 Béguin (10.1111/j.1538-7933.2004.00618.x_bb0040) 1989; 61 Briedé (10.1111/j.1538-7933.2004.00618.x_bb0075) 2003; 1 Feijge (10.1111/j.1538-7933.2004.00618.x_bb0125) 1998; 102 Reverter (10.1111/j.1538-7933.2004.00618.x_bb0045) 1996; 98 Dörmann (10.1111/j.1538-7933.2004.00618.x_bb0065) 2000; 96 Heemskerk (10.1111/j.1538-7933.2004.00618.x_bb0115) 1997; 249 Hemker (10.1111/j.1538-7933.2004.00618.x_bb0010) 1964 Jacobsson (10.1111/j.1538-7933.2004.00618.x_bb0090) 2002; 24 Vanschoonbeek (10.1111/j.1538-7933.2004.00618.x_bb0145) 2002; 88 Solum (10.1111/j.1538-7933.2004.00618.x_bb0035) 1999; 19 Hemker (10.1111/j.1538-7933.2004.00618.x_bb0095) 2000; 83 Bevers (10.1111/j.1538-7933.2004.00618.x_bb0165) 1982; 122 Butenas (10.1111/j.1538-7933.2004.00618.x_bb0060) 2001; 97 Dicker (10.1111/j.1538-7933.2004.00618.x_bb0070) 2001; 86 Furman (10.1111/j.1538-7933.2004.00618.x_bb0155) 2000; 84 Thomas (10.1111/j.1538-7933.2004.00618.x_bb0055) 2000; 84 Baird (10.1111/j.1538-7933.2004.00618.x_bb0030) 2002; 277 Herault (10.1111/j.1538-7933.2004.00618.x_bb0085) 1999; 57 Nieuwenhuys (10.1111/j.1538-7933.2004.00618.x_bb0120) 2000; 84 Zwaal (10.1111/j.1538-7933.2004.00618.x_bb0015) 1997; 89 Hemker (10.1111/j.1538-7933.2004.00618.x_bb0105) 1995; 74 Li (10.1111/j.1538-7933.2004.00618.x_bb0150) 1998; 9 Alberio (10.1111/j.1538-7933.2004.00618.x_bb0160) 2000; 95 Storey (10.1111/j.1538-7933.2004.00618.x_bb0080) 2000; 110 Huntington (10.1111/j.1538-7933.2004.00618.x_bb0140) 2003; 24 |
| References_xml | – volume: 88 start-page: 186 year: 2002 end-page: 93 article-title: Platelet activation and blood coagulation publication-title: Thromb Haemost – volume: 86 start-page: 1065 year: 2001 end-page: 9 article-title: Both the high affinity thrombin receptor (GPIb‐IX‐V) and GPIIb/IIIa are implicated in expression of thrombin‐induced platelet procoagulant activity publication-title: Thromb Haemost – volume: 95 start-page: 1694 year: 2000 end-page: 702 article-title: Surface expression and functional characterization of α‐granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin publication-title: Blood – volume: 249 start-page: 547 year: 1997 end-page: 55 article-title: The Ca ‐mobilizing potency of α‐thrombin and thrombin‐receptor‐activating peptide on human platelets publication-title: Eur J Biochem – volume: 102 start-page: 850 year: 1998 end-page: 9 article-title: Inter‐individual variability in Ca signalling in platelets from healthy volunteers publication-title: Br J Haematol – volume: 24 start-page: 589 year: 2003 end-page: 95 article-title: Targeting thrombin: rational drug design from natural mechanisms publication-title: Trends Pharmacol Sci – volume: 110 start-page: 925 year: 2000 end-page: 34 article-title: The central role of the P2 receptor in amplification of human platelet activation, secretion and procoagulant activity publication-title: Br J Haematol – volume: 122 start-page: 429 year: 1982 end-page: 36 article-title: Generation of prothrombin‐converting activity and the exposure of phosphatidylserine at the outer surface of platelets publication-title: Eur J Biochem – volume: 98 start-page: 863 year: 1996 end-page: 74 article-title: Inhibition of platelet‐mediated, tissue factor‐induced thrombin generation by the mouse/human chimeric 7E3 antibody publication-title: J Clin Invest – volume: 22 start-page: 1381 year: 2002 end-page: 9 article-title: Platelets and thrombin generation publication-title: Arterioscler Thromb Vasc Biol – volume: 277 start-page: 38462 year: 2002 end-page: 7 article-title: The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation publication-title: J Biol Chem – volume: 19 start-page: 2841 year: 1999 end-page: 6 article-title: Procoagulant expression in platelets and defects leading to clinical disorders publication-title: Arterioscl Thromb Vasc Biol – volume: 83 start-page: 589 year: 2000 end-page: 91 article-title: The thrombogram: monitoring thrombin generation in platelet‐rich plasma publication-title: Thromb Haemost – volume: 84 start-page: 492 year: 2000 end-page: 8 article-title: GPIIb‐IIIa antagonist‐induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood publication-title: Thromb Haemost – volume: 1 start-page: 559 year: 2003 end-page: 65 article-title: Von Willebrand factor mediates thrombin‐induced exposure of procoagulant phospholipids on the surface of fibrin‐adherent platelets publication-title: J Thromb Haemost – start-page: 477 year: 1964 end-page: 90 – volume: 84 start-page: 98 year: 2000 end-page: 103 article-title: Monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibα inhibit platelet dependent thrombin generation by different mechanisms publication-title: Thromb Haemost – volume: 96 start-page: 2469 year: 2000 end-page: 78 article-title: The GPIb thrombin‐binding site is essential for thrombin‐induced platelet procoagulant activity publication-title: Blood – volume: 84 start-page: 1045 year: 2000 end-page: 51 article-title: Monitoring hypocoagulant conditions in rat plasma: factors determining the endogenous thrombin potential of tissue factor‐activated plasma publication-title: Thromb Haemost – volume: 9 start-page: 507 year: 1998 end-page: 15 article-title: Effects of a new platelet glycoprotein IIb/IIIa antagonist, SR121566, on platelet activation, platelet–leukocyte interaction and thrombin generation publication-title: Blood Coagul Fibrinolysis – volume: 88 start-page: 931 year: 2002 end-page: 7 article-title: Thrombin‐induced hyperactivity of platelets of young stroke patients publication-title: Thromb Haemost – volume: 97 start-page: 1680 year: 1998 end-page: 8 article-title: Pharmacodynamic profile of short‐term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade publication-title: Circulation – volume: 33 start-page: 4 year: 2003 end-page: 15 article-title: Calibrated automated thrombin generation measurement in clotting plasma publication-title: Pathophysiol Haemost Thromb – volume: 21 start-page: 618 year: 2001 end-page: 27 article-title: Platelet adhesion enhances the glycoprotein VI‐dependent procoagulant response: involvement of p38 MAP kinase and calpain publication-title: Arterioscler Thromb Vasc Biol – volume: 90 start-page: 2615 year: 1997 end-page: 25 article-title: Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine and procoagulant activity of adherent platelets publication-title: Blood – volume: 24 start-page: 752 year: 2002 end-page: 65 article-title: Safety profile and tolerability of intravenous AR‐C69931MX, a new antiplatelet drug, in unstable angina pectoris and non‐Q‐wave myocardial infarction publication-title: Clin Ther – volume: 57 start-page: 603 year: 1999 end-page: 10 article-title: Activation of human vascular endothelial cells by factor Xa, effect of specific inhibitors publication-title: Biochem Pharmacol – volume: 89 start-page: 1121 year: 1997 end-page: 32 article-title: Pathophysiological implications of membrane phospholipid asymmetry in blood cells publication-title: Blood – volume: 97 start-page: 2314 year: 2001 end-page: 22 article-title: Antiplatelet agents in tissue factor‐induced blood coagulation publication-title: Blood – volume: 61 start-page: 25 year: 1989 end-page: 9 article-title: The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma; its inhibition by heparin publication-title: Thromb Haemost – volume: 79 start-page: 383 year: 1998 end-page: 8 article-title: Effect of SR121566A, a potent GP IIb‐IIIa antagonist on platelet‐mediated thrombin generation and publication-title: Thromb Haemost – volume: 74 start-page: 134 year: 1995 end-page: 8 article-title: Thrombin generation in plasma: its assessment via the endogenous thrombin potential publication-title: Thromb Haemost – volume: 84 start-page: 1045 year: 2000 ident: 10.1111/j.1538-7933.2004.00618.x_bb0120 article-title: Monitoring hypocoagulant conditions in rat plasma: factors determining the endogenous thrombin potential of tissue factor‐activated plasma publication-title: Thromb Haemost doi: 10.1055/s-0037-1614169 – volume: 33 start-page: 4 year: 2003 ident: 10.1111/j.1538-7933.2004.00618.x_bb0100 article-title: Calibrated automated thrombin generation measurement in clotting plasma publication-title: Pathophysiol Haemost Thromb doi: 10.1159/000071636 – volume: 24 start-page: 589 year: 2003 ident: 10.1111/j.1538-7933.2004.00618.x_bb0140 article-title: Targeting thrombin: rational drug design from natural mechanisms publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2003.09.002 – volume: 86 start-page: 1065 year: 2001 ident: 10.1111/j.1538-7933.2004.00618.x_bb0070 article-title: Both the high affinity thrombin receptor (GPIb‐IX‐V) and GPIIb/IIIa are implicated in expression of thrombin‐induced platelet procoagulant activity publication-title: Thromb Haemost doi: 10.1055/s-0037-1616534 – volume: 249 start-page: 547 year: 1997 ident: 10.1111/j.1538-7933.2004.00618.x_bb0115 article-title: The Ca2+‐mobilizing potency of α‐thrombin and thrombin‐receptor‐activating peptide on human platelets publication-title: Eur J Biochem doi: 10.1111/j.1432-1033.1997.00547.x – volume: 102 start-page: 850 year: 1998 ident: 10.1111/j.1538-7933.2004.00618.x_bb0125 article-title: Inter‐individual variability in Ca2+ signalling in platelets from healthy volunteers publication-title: Br J Haematol doi: 10.1046/j.1365-2141.1998.00844.x – volume: 24 start-page: 752 year: 2002 ident: 10.1111/j.1538-7933.2004.00618.x_bb0090 article-title: Safety profile and tolerability of intravenous AR‐C69931MX, a new antiplatelet drug, in unstable angina pectoris and non‐Q‐wave myocardial infarction publication-title: Clin Ther doi: 10.1016/S0149-2918(02)85149-9 – volume: 74 start-page: 134 year: 1995 ident: 10.1111/j.1538-7933.2004.00618.x_bb0105 article-title: Thrombin generation in plasma: its assessment via the endogenous thrombin potential publication-title: Thromb Haemost doi: 10.1055/s-0038-1642666 – volume: 79 start-page: 383 year: 1998 ident: 10.1111/j.1538-7933.2004.00618.x_bb0050 article-title: Effect of SR121566A, a potent GP IIb‐IIIa antagonist on platelet‐mediated thrombin generation in vitro and in vivo publication-title: Thromb Haemost doi: 10.1055/s-0037-1614996 – volume: 83 start-page: 589 year: 2000 ident: 10.1111/j.1538-7933.2004.00618.x_bb0095 article-title: The thrombogram: monitoring thrombin generation in platelet‐rich plasma publication-title: Thromb Haemost doi: 10.1055/s-0037-1613868 – volume: 98 start-page: 863 year: 1996 ident: 10.1111/j.1538-7933.2004.00618.x_bb0045 article-title: Inhibition of platelet‐mediated, tissue factor‐induced thrombin generation by the mouse/human chimeric 7E3 antibody publication-title: J Clin Invest doi: 10.1172/JCI118859 – volume: 88 start-page: 931 year: 2002 ident: 10.1111/j.1538-7933.2004.00618.x_bb0145 article-title: Thrombin‐induced hyperactivity of platelets of young stroke patients publication-title: Thromb Haemost doi: 10.1055/s-0037-1613336 – volume: 96 start-page: 2469 year: 2000 ident: 10.1111/j.1538-7933.2004.00618.x_bb0065 article-title: The GPIb thrombin‐binding site is essential for thrombin‐induced platelet procoagulant activity publication-title: Blood doi: 10.1182/blood.V96.7.2469 – volume: 97 start-page: 1680 year: 1998 ident: 10.1111/j.1538-7933.2004.00618.x_bb0130 article-title: Pharmacodynamic profile of short‐term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade publication-title: Circulation doi: 10.1161/01.CIR.97.17.1680 – volume: 9 start-page: 507 year: 1998 ident: 10.1111/j.1538-7933.2004.00618.x_bb0150 article-title: Effects of a new platelet glycoprotein IIb/IIIa antagonist, SR121566, on platelet activation, platelet–leukocyte interaction and thrombin generation publication-title: Blood Coagul Fibrinolysis doi: 10.1097/00001721-199809000-00008 – volume: 97 start-page: 2314 year: 2001 ident: 10.1111/j.1538-7933.2004.00618.x_bb0060 article-title: Antiplatelet agents in tissue factor‐induced blood coagulation publication-title: Blood doi: 10.1182/blood.V97.8.2314 – start-page: 477 year: 1964 ident: 10.1111/j.1538-7933.2004.00618.x_bb0010 article-title: Thrombin generation, an essential step in haemostasis and thrombosis – volume: 21 start-page: 618 year: 2001 ident: 10.1111/j.1538-7933.2004.00618.x_bb0110 article-title: Platelet adhesion enhances the glycoprotein VI‐dependent procoagulant response: involvement of p38 MAP kinase and calpain publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.21.4.618 – volume: 110 start-page: 925 year: 2000 ident: 10.1111/j.1538-7933.2004.00618.x_bb0080 article-title: The central role of the P2T receptor in amplification of human platelet activation, secretion and procoagulant activity publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2000.02208.x – volume: 22 start-page: 1381 year: 2002 ident: 10.1111/j.1538-7933.2004.00618.x_bb0025 article-title: Platelets and thrombin generation publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000031340.68494.34 – volume: 95 start-page: 1694 year: 2000 ident: 10.1111/j.1538-7933.2004.00618.x_bb0160 article-title: Surface expression and functional characterization of α‐granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin publication-title: Blood doi: 10.1182/blood.V95.5.1694.005k24_1694_1702 – volume: 61 start-page: 25 year: 1989 ident: 10.1111/j.1538-7933.2004.00618.x_bb0040 article-title: The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma; its inhibition by heparin publication-title: Thromb Haemost doi: 10.1055/s-0038-1646521 – volume: 277 start-page: 38462 year: 2002 ident: 10.1111/j.1538-7933.2004.00618.x_bb0030 article-title: The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation publication-title: J Biol Chem doi: 10.1074/jbc.M205902200 – volume: 90 start-page: 2615 year: 1997 ident: 10.1111/j.1538-7933.2004.00618.x_bb0135 article-title: Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine and procoagulant activity of adherent platelets publication-title: Blood doi: 10.1182/blood.V90.7.2615 – volume: 84 start-page: 492 year: 2000 ident: 10.1111/j.1538-7933.2004.00618.x_bb0155 article-title: GPIIb‐IIIa antagonist‐induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood publication-title: Thromb Haemost doi: 10.1055/s-0037-1614050 – volume: 19 start-page: 2841 year: 1999 ident: 10.1111/j.1538-7933.2004.00618.x_bb0035 article-title: Procoagulant expression in platelets and defects leading to clinical disorders publication-title: Arterioscl Thromb Vasc Biol doi: 10.1161/01.ATV.19.12.2841 – volume: 88 start-page: 186 year: 2002 ident: 10.1111/j.1538-7933.2004.00618.x_bb0020 article-title: Platelet activation and blood coagulation publication-title: Thromb Haemost doi: 10.1055/s-0037-1613209 – volume: 84 start-page: 98 year: 2000 ident: 10.1111/j.1538-7933.2004.00618.x_bb0055 article-title: Monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibα inhibit platelet dependent thrombin generation by different mechanisms publication-title: Thromb Haemost doi: 10.1055/s-0037-1613975 – volume: 1 start-page: 559 year: 2003 ident: 10.1111/j.1538-7933.2004.00618.x_bb0075 article-title: Von Willebrand factor mediates thrombin‐induced exposure of procoagulant phospholipids on the surface of fibrin‐adherent platelets publication-title: J Thromb Haemost doi: 10.1046/j.1538-7836.2003.00077.x – volume: 122 start-page: 429 year: 1982 ident: 10.1111/j.1538-7933.2004.00618.x_bb0165 article-title: Generation of prothrombin‐converting activity and the exposure of phosphatidylserine at the outer surface of platelets publication-title: Eur J Biochem doi: 10.1111/j.1432-1033.1982.tb05898.x – volume: 89 start-page: 1121 year: 1997 ident: 10.1111/j.1538-7933.2004.00618.x_bb0015 article-title: Pathophysiological implications of membrane phospholipid asymmetry in blood cells publication-title: Blood doi: 10.1182/blood.V89.4.1121 – volume: 57 start-page: 603 year: 1999 ident: 10.1111/j.1538-7933.2004.00618.x_bb0085 article-title: Activation of human vascular endothelial cells by factor Xa, effect of specific inhibitors publication-title: Biochem Pharmacol doi: 10.1016/S0006-2952(98)00348-7 |
| SSID | ssj0019520 |
| Score | 2.1422846 |
| Snippet | The hemostatic activity of plasma is determined by platelet activation and coagulation, which processes are mutually stimulatory. We studied this interaction... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 476 |
| SubjectTerms | Blood Platelets - physiology coagulation Female Humans Kinetics Male phosphatidylserine Phospholipids - blood platelets Reference Values thrombin Thrombin - metabolism Thromboplastin - physiology |
| Title | Initiating and potentiating role of platelets in tissue factor‐induced thrombin generation in the presence of plasma: subject‐dependent variation in thrombogram characteristics |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1538-7933.2004.00618.x https://www.ncbi.nlm.nih.gov/pubmed/15009466 https://www.proquest.com/docview/71716930 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JSsRAEG1kDuLFfRnXPnjNkKSzehNxGIXxIApzC-klKjqZwSQinvwEP8Yv8kus6iwa9SDiLYRUhaaquqq7X78iZN-HtK5sUxphjFs3kjsGB2MYygwVQ1yN1O2Ahmfe4NI5HbmjCv-Ed2FKfohmww0jQ8_XGOAxz9pBjsEK_sX0Mg8RWlbQw3oSoVtYH503TFJW6GqGxkakDer5UVE7U30rP9vVrE5H_QVyWw-kRKHc9oqc98TTF47H_xnpIpmvqlZ6WLrZEplR6TKZHVbn8ivk9QQxSDFCqGmcSjqd5IhCKl8ggJFOEjq9g7oW3CSjNynNtcFp2e7n7fnlJpXgZJJi24YxrNbplebDRrfRn18rOtU3pUStKxvHBzQrOG4kgYK6m29OH2D5_0kQ9WkMGhVtcupVctk_vjgaGFU_CEM4gRkYgTTNxA4kc3kSJpBZHS-Q3E4s2_JCR3hSiIRZArItS3xHCZNLpRKfY39l6TPG1kgnnaRqg1Co87zYlHhtF_mFLJhqpecKLmy8qWuLLvFr20eiIkvHnh130adFExglQqNgK08n0kaJHrvEaiSnJWHIL2T2aveKILrxyCZO1aTIIl-zGTGzS9ZLr_vQ6SIo1PO6xNW-8-ufRacXA3jY_KPcFpkrwUsIw9smnfy-UDtQl-V8V0fcO-mGLW8 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NTttAEB5VILW9QFvaEvqTPXB1ZHv9yw1VjQIlOVRB4rby_riNGpwocRDixCPwMDwRT9KZtZ3iwgFVvVmRZyJrZjyz62-_D2A_xrZufFc7aUZbN1oGjsRgOMZNDSdcjbZyQMNRNDgNjs_Cs1oOiM7CVPwQ6w03qgz7vqYCpw3pdpVTtWKCcbvOI4iWl_RwoNwkgW-7vvq-5pLy0tByNK5t2rCeRz21e9WDAbQ9z9qG1N-GafMoFQ7lV29Vyp66-ovl8T896yvYqgdXdlhl2mt4Zoo38HxYf5rfgdsjgiFlhKJmWaHZfFYSEKn6gTCMbJaz-RRHW8yUJZsUrLQxZ5Xiz931zaTQmGeakXLDOS7Y2Q9LiU2ZY2__adjcHpZSja_leXbAlitJe0nooBH0LdlFtpjcMyR_FobGVJuf-i2c9r-OvwycWhLCUUHiJk6iXTf3E81Dmac5NtcgSrT0c8_3ojRQkVYq557ChsvzODDKldqYPJYksaxjzvk72ChmhdkFhqNelLmaTu4SxZCHb1sdhUoqnw7r-qoDcRN8oWq-dJLtmIp76yYMiqCgkJpnIGxQxGUHvLXlvOIMeYJNt8kvgQVOX22ywsxWSxFbQiPuduB9lXZ_fIaEC42iDoQ2eZ78Z-J4PMCLvX-068KLwXh4Ik6ORt8-wMsKy0SovI-wUS5W5hOOaaX8bMvvN6zqMYo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JbtRAEC2hIEVc2JcJS_rA1aO2227b3BBhNAkkQiiRcmu5N4iSeCzGEyFOfAIfwxfxJVS17SEGDhHiZo1cNbLqlau6_foVwPMcy7pLuI3KirZurE4jjcGIHC-dIF6NDeOA9g_k_CjdO86Oe_4TnYXp9CHWG26UGeF9TQneWD9OckpWxJcIyzxiaMXFFPvJ66nkBSF85_1aSiousyDRuLYZs3r-6mlcqv7oP8ftbKhHs1twOjxJR0M5na5aPTVffhN5_D-Pehtu9m0re9nh7A5cc_Vd2NzvP8zfg--7REKqiEPNqtqyZtESDan7gRiMbOFZc4aNLeJkyU5q1oaIs27ez4-v305qiyizjOY2nONynX0IgtiEm3D7R8eacFTKDL6W59ULtlxp2klCB8M435Zd4Pr_kiH5CyQ0Zsbq1PfhaPb68NU86gdCRCYteBEVlnOfFFZk2pceS2sqC6sTHyexLFMjrTFexAbLrfB56gzX1jmfaxqwbHMhxAPYqBe1ewQMGz1ZcUvndklgKMZ3rZWZ0Saho7qJmUA-xF6ZXi2dhnacqUurJgyKoqDQLM9UhaCozxOI15ZNpxhyBZvtAV4K05u-2VS1W6yWKg9yRoJP4GGHul8-M2KFSjmBLGDnyn-m9g7neLH1j3bbsPluZ6be7h68eQw3OiITUfKewEb7aeWeYo_W6mch-X4CCtkwQg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Initiating+and+potentiating+role+of+platelets+in+tissue+factor-induced+thrombin+generation+in+the+presence+of+plasma%3A+subject-dependent+variation+in+thrombogram+characteristics&rft.jtitle=Journal+of+thrombosis+and+haemostasis&rft.au=Vanschoonbeek%2C+K&rft.au=Feijge%2C+M+A+H&rft.au=Van+Kampen%2C+R+J+W&rft.au=Kenis%2C+H&rft.date=2004-03-01&rft.issn=1538-7933&rft.volume=2&rft.issue=3&rft.spage=476&rft_id=info:doi/10.1111%2Fj.1538-7933.2004.00618.x&rft_id=info%3Apmid%2F15009466&rft.externalDocID=15009466 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7933&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7933&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7933&client=summon |